pros and cons of glp 1 GLP-1 weight loss medications have significant side effects In my latest blog, The

Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity A Phase 2 Trial

For example, the FDAs approval of Lillys ZepBound (tirzepatide for chronic weight management) in late 2023 was based on phase III data showing superior weight loss compared to placebo

Significance : This trial specifically evaluated semaglutide in individuals WITH type 2 diabetes, demonstrating efficacy and safety in this population

Overall, GLP-1 and GLP1-Rs are major components of the gut/brain axis and, through the multiple functions that they exert, may be a promising therapeutic target for PD

GLP-1RAs and related incretin-based therapies contribute to sustained weight loss in obese individuals, which is accompanied by improvements in related comorbidities

doi: 10.1007/s13300-022-01218-y